Biomarin Pharmaceutical (BMRN) Net Cash Flow (QoQ) (2009 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -224.78% |
| Mar 31, 2026 | 2,815.14% |
| Dec 31, 2025 | 69.75% |
| Sep 30, 2025 | -78.85% |
| Jun 30, 2025 | 56.53% |
| Mar 31, 2025 | -59.46% |
| Dec 31, 2024 | 190.16% |
| Sep 30, 2024 | -232.43% |
| Jun 30, 2024 | 2,305.75% |
| Mar 31, 2024 | 62.24% |
| Dec 31, 2023 | -129.91% |
| Sep 30, 2023 | -20.17% |
| Jun 30, 2023 | 177.10% |
| Mar 31, 2023 | -290.46% |
| Dec 31, 2022 | -126.01% |
| Sep 30, 2022 | 866.03% |
| Jun 30, 2022 | -13.61% |
| Mar 31, 2022 | 157.20% |
| Dec 31, 2021 | -25.30% |
| Sep 30, 2021 | 10.20% |